🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo

    Spero Therapeutics

    TQT Study

    phase 1 small molecule completed

    1 trial

  2. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

    Spero Therapeutics

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  3. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  4. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  5. Tebipenem tablet form

    Spero Therapeutics

    Relative Bioavailability

    phase 1 small molecule completed

    1 trial

  6. Telavancin

    Theravance Biopharma Ireland Umited

    Healthy

    phase 1 small molecule completed

    1 trial

  7. Telotristat etiprate

    LEXICON PHARMACEUTICALS, INC.

    Drug Interactions

    phase 1 small molecule completed

    2 trials

  8. Tepotinib

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  9. The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune Diseases

    Century Therapeutics

    systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]

    phase 1 other active

    1 trial

  10. The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)

    Sinobioway Cell Therapy Co.,

    Lymphoma

    phase 1 mab active

    1 trial

  11. Therapeutic Workplace Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Addiction

    phase 1 other completed

    1 trial

  12. Tofacitinib tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Amyotrophic Lateral Sclerosis

    phase 1 small molecule active

    1 trial

  13. Training with 4D Motion Capture Device

    4D Molecular Therapeutics

    Stroke

    phase 1 other completed

    1 trial

  14. TransCon PEG treprostinil

    United Therapeutics Europe Ltd

    PAH

    phase 1 small molecule terminated

    1 trial

  15. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  16. Treprostinil Inhalation Powder

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 1 small molecule completed

    1 trial

  17. Treprostinil diethanolamine

    United Therapeutics Europe Ltd

    Hypertension, Pulmonary

    phase 1 small molecule completed

    2 trials

  18. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  19. UB-221

    United Therapeutics Europe Ltd

    Urticaria Chronic

    phase 1 mab completed

    1 trial

  20. UB-221

    United Therapeutics Europe Ltd

    Chronic Idiopathic Urticaria

    phase 1 small molecule active

    1 trial

  21. UB-421 SC

    United Therapeutics Europe Ltd

    HIV-1-infection

    phase 1 mab active

    1 trial

  22. UB-421 SC(dB4C7C22-6 mAb)

    United Therapeutics Europe Ltd

    HIV-1 Infection

    phase 1 mab completed

    1 trial

  23. UB-621

    United Therapeutics Europe Ltd

    Herpes Simplex Virus Infection

    phase 1 small molecule completed

    1 trial

  24. UB-921

    United Therapeutics Europe Ltd

    Breast Neoplasm

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources